yingweiwo

Roxatidine acetate (HOE 760)

Cat No.:V8859 Purity: ≥98%
Roxatidine acetate is a potent, selective, competitive, orally bioactive histamine H2-receptor blocker (antagonist).
Roxatidine acetate (HOE 760)
Roxatidine acetate (HOE 760) Chemical Structure CAS No.: 78628-28-1
Product category: New1
This product is for research use only, not for human use. We do not sell to patients.
Size Price
500mg
1g
Other Sizes

Other Forms of Roxatidine acetate (HOE 760):

  • Roxatidine acetate HCl (HOE 760)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
Roxatidine acetate is a potent, selective, competitive, orally bioactive histamine H2-receptor blocker (antagonist). Roxatidine acetate has antisecretory effects on gastric acid secretion. Roxatidine acetate also inhibits inflammatory responses and may be utilized in research on gastric ulcers and duodenal ulcers. Roxatidine acetate has anti-tumor effects.
Roxatidine acetate is a potent, selective, competitive, orally bioactive histamine H2-receptor antagonist. It inhibits gastric acid secretion by blocking H2 receptors on parietal cells, with antisecretory, anti-inflammatory, and antitumor effects. It is used in research on peptic ulcers, gastritis, gastroesophageal reflux disease, and inflammatory responses.
Biological Activity I Assay Protocols (From Reference)
Targets
The primary target is the histamine H2 receptor on gastric parietal cells, where roxatidine acts as a competitive antagonist. By blocking H2 receptors, it inhibits histamine-stimulated acid secretion. Additional anti-inflammatory effects involve inhibition of NF-κB and p38 MAPK activation, and suppression of pro-inflammatory cytokine and mediator production (TNF-α, IL-1β, IL-6, PGE2, NO).
ln Vitro
In RAW 264.7 macrophages, roxatidineacetate (0-120μM, 1 hour) suppresses inflammatory responses by blocking LPS-induced NF-κB and p38MAPK activation [2]. PMACI-induced p38MAPK activation is inhibited by roxatidineacetate (6.25 μM, 12.5 μM, and 25 μM; 30 min pretreatment), but phosphorylation of ERK and JNK is unaffected. Roxatidine had no effect on the levels of total ERK 1/2, JNK, or p38 MAPK in human mast cell-1 (HMC-1) cells [4].
In RAW 264.7 macrophages, roxatidine acetate (40-120 µM) suppresses LPS-induced PGE2, NO, and histamine production, and inhibits COX-2, iNOS, and HDC expression. It reduces TNF-α, IL-1β, IL-6, and VEGF-1 expression, attenuates nuclear translocation of p65 and p50, and inhibits LPS-induced p38 MAPK phosphorylation. In HMC-1 cells (6.25-25 µM), it inhibits PMACI-induced p38 MAPK activation without affecting ERK or JNK.
ln Vivo
Roxatidine acetate (0-300 mg/kg; oral; 26 days) slows the growth of colonic 38 tumor implants in mice [3]. Roxatidineacetate (oral gavage; 20 mg/kg; single dosage) suppresses compound 48/80-increased TNF-α, IL-6, and IL-1β production and mRNA expression. In addition, Roxatidine inhibits compound 48/80-induced procaspase-1 degradation and the formation of the matching cleavage band in mice [4].
In mice, oral roxatidine acetate (30-300 mg/kg, 26 days) slows the growth of colonic 38 tumor implants in a dose-related manner and reduces VEGF levels in tumor tissues and serum. At 20 mg/kg (oral gavage), it suppresses compound 48/80-induced production of TNF-α, IL-6, and IL-1β, and inhibits procaspase-1 degradation in allergic inflammation models. Oral bioavailability is 80-90%.
Enzyme Assay
H2 receptor binding is assessed using membrane preparations from guinea pig brain or cells expressing recombinant human H2 receptors. Membranes are incubated with [³H]-tiotidine (1-5 nM) and varying concentrations of roxatidine acetate (0.1-1000 nM) in 50 mM phosphate buffer (pH 7.4) for 60 minutes at 25°C. Nonspecific binding is determined with 100 µM cimetidine. Bound radioactivity is collected on GF/B filters and counted. IC₅₀ and Ki are calculated.
Cell Assay
Western Blot Analysis[2]
Cell Types: RAW 264.7
Tested Concentrations: 40, 80 and 120 μM
Incubation Duration: 1 hour
Experimental Results: Inhibition of LPS-induced PGE2, NO and histamine production as well as COX-2, iNOS and HDC expression. Inhibits the expression of TNF-α, IL-1β, IL-6 and VEGF-1. Nuclear translocation of p65 and p50 was attenuated in a concentration-dependent manner. Inhibits LPS-induced phosphorylation of p38 MAP kinase. Dramatically downregulates LPS-induced NO and PGE2 (prostaglandin E2) production.
RAW 264.7 macrophages or HMC-1 cells are cultured and treated with roxatidine acetate (0-120 µM) for 1 hour, followed by stimulation with LPS (1 µg/mL) or PMACI for 0.5-24 hours. Protein expression (COX-2, iNOS, HDC, phospho-p38, total p38) is analyzed by Western blot. Cytokine and mediator levels in culture supernatants are measured by ELISA (TNF-α, IL-1β, IL-6, PGE2) or Griess assay (NO). Nuclear translocation of NF-κB subunits is assessed by immunofluorescence or nuclear-cytoplasmic fractionation.
Animal Protocol
Animal/Disease Models: Male C57BL/6 colon38 mice (8 weeks old, 20 – 22 g) [3]
Doses: 30, 100 and 300 mg/kg daily, 1 ml/100 g body weight orally, from colon38 Day 29 started 3 days before implantation, or day 26 started simultaneously with colon 38 implantation.
Experimental Results: After day 26, colon 38 tumor implant growth was inhibited in a dose-related manner. Inhibits VEGF levels in tumor tissues and Dramatically reduces serum VEGF levels.
Animal/Disease Models: ICR male mice (6 weeks old) [4]
Doses: 20 mg/kg
Route of Administration: po (oral gavage); 20 mg/kg; single dose
Experimental Results: Inhibition of compound 48/80 induction in allergic animal models allergic inflammation.
Male C57BL/6 mice bearing colon 38 tumors (8 weeks old, 20-22 g) receive oral roxatidine acetate (30-300 mg/kg daily, 1 mL/100 g body weight) starting 3 days before or on the day of tumor implantation for up to 26 days. Tumor growth is measured with calipers. VEGF levels in serum and tumor tissues are quantified by ELISA. In ICR male mice (6 weeks old), roxatidine acetate is given orally at 20 mg/kg (single dose) before compound 48/80 challenge; inflammatory markers and procaspase-1 cleavage are analyzed in peritoneal lavage fluid and tissues.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Good oral absorption (bioavailability 80–90%). Metabolism/Metabolites Roxane acetate is rapidly metabolized to the major active metabolite, deacetyl metabolite. Biological Half-Life 5–6 hours
Toxicity/Toxicokinetics
Protein Binding
5-7%
References

[1]. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. Drugs. 1991 Aug;42(2):240-60.

[2]. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem. 2011 Dec;112(12):3648-59.

[3]. Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci. 2003 Nov;93(3):321-30.

[4]. Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation. Sci Rep. 2017 Jan 31;7:41721.

Additional Infomation
Roxane belongs to the piperidine class of drugs. Roxane acetate is a specific competitive H2 receptor antagonist. It is currently approved for marketing in South Africa under the brand name Roxit. See also: hydrochlorothiazide (note moved to); Roxane (note moved to). Indications: Used to treat upper gastrointestinal disorders caused by excessive hydrochloric acid in gastric juice, such as duodenal ulcers and benign gastric ulcers. It can also be used to prevent recurrent gastric and duodenal ulcers. Mechanism of Action: H2 receptor antagonists are competitive inhibitors of histamine on parietal cell H2 receptors. They inhibit normal gastric acid secretion from parietal cells as well as gastric acid secretion induced by food intake. They achieve this through two mechanisms: histamine released from gastric ECL cells is blocked from binding to H2 receptors on parietal cells, thereby inhibiting gastric acid secretion; other substances that promote gastric acid secretion (such as gastrin and acetylcholine) have reduced effects on parietal cells after H2 receptor blockade.
Pharmacodynamics
Roxane acetate inhibits the effect of histamine on gastric parietal cells (H2 receptor antagonist). This inhibition is dose-dependent. Therefore, the production and secretion of gastric acid, especially gastric acid, are reduced. Roxane acetate has no anti-androgenic effect and does not affect drug-metabolizing enzymes in the liver.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C19H28N2O4
Molecular Weight
348.43662
Exact Mass
348.204
CAS #
78628-28-1
Related CAS #
Roxatidine Acetate Hydrochloride;93793-83-0
PubChem CID
5105
Appearance
Typically exists as solid at room temperature
Density
1.1±0.1 g/cm3
Boiling Point
537.3±45.0 °C at 760 mmHg
Melting Point
225 °C (dec.)(lit.)
Flash Point
278.7±28.7 °C
Vapour Pressure
0.0±1.4 mmHg at 25°C
Index of Refraction
1.533
LogP
2
tPSA
67.87
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
5
Rotatable Bond Count
10
Heavy Atom Count
25
Complexity
410
Defined Atom Stereocenter Count
0
SMILES
CC(OCC(NCCCOC1=CC=CC(CN2CCCCC2)=C1)=O)=O
InChi Key
SMTZFNFIKUPEJC-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)
Chemical Name
[2-oxo-2-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]ethyl] acetate
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.8699 mL 14.3497 mL 28.6993 mL
5 mM 0.5740 mL 2.8699 mL 5.7399 mL
10 mM 0.2870 mL 1.4350 mL 2.8699 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration: mg/mL;

Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Contact Us